Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) EBITDA Margin (2019 - 2025)

Nurix Therapeutics (NRIX) has disclosed EBITDA Margin for 7 consecutive years, with 612.03% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 12530.0% to 612.03% in Q4 2025 year-over-year; TTM through Nov 2025 was 326.73%, a 6380.0% increase, with the full-year FY2025 number at 340.16%, up 5036.0% from a year prior.
  • EBITDA Margin was 612.03% for Q4 2025 at Nurix Therapeutics, up from 805.37% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 87.25% in Q2 2023 to a low of 805.37% in Q3 2025.
  • A 5-year average of 402.84% and a median of 400.65% in 2022 define the central range for EBITDA Margin.
  • Peak YoY movement for EBITDA Margin: skyrocketed 41877bps in 2023, then crashed -37153bps in 2025.
  • Nurix Therapeutics' EBITDA Margin stood at 513.16% in 2021, then tumbled by -40bps to 717.82% in 2022, then surged by 58bps to 299.06% in 2023, then plummeted by -63bps to 486.73% in 2024, then decreased by -26bps to 612.03% in 2025.
  • Per Business Quant, the three most recent readings for NRIX's EBITDA Margin are 612.03% (Q4 2025), 805.37% (Q3 2025), and 109.68% (Q2 2025).